Exact Sciences
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 1.5b | 1.8b | 2.1b | 2.5b | 2.8b | 3.2b | 3.6b |
% growth | 70 % | 18 % | 18 % | 20 % | 13 % | 14 % | 12 % |
EBITDA | (465m) | (740m) | (480m) | (13.1m) | 348m | 517m | 695m |
% EBITDA margin | (31 %) | (42 %) | (23 %) | (1 %) | 12 % | 16 % | 19 % |
Profit | (849m) | (596m) | (624m) | (204m) | (165m) | (11.9m) | 148m |
% profit margin | (57 %) | (34 %) | (30 %) | (8 %) | (6 %) | - | 4 % |
EV / revenue | 13.8x | 8.2x | 5.0x | 6.0x | 4.6x | 4.0x | 3.4x |
EV / EBITDA | -44.3x | -19.7x | -21.7x | -1135.8x | 37.7x | 24.7x | 17.5x |
R&D budget | 554m | 386m | 393m | 426m | - | - | - |
R&D % of revenue | 37 % | 22 % | 19 % | 17 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
N/A | $8.2m | Early VC | |
* | N/A | $600m | Post IPO Debt |
* | N/A | $850m | Post IPO Debt |
* | N/A | $500m | Post IPO Convertible |
* | $204k | Post IPO Equity | |
* | N/A | $621m | Post IPO Convertible |
Total Funding | CAD11.2m |
Related Content
Recent News about Exact Sciences
EditExact Sciences is a biotechnology company focused on the early detection and prevention of cancer. Headquartered in Madison, Wisconsin, the company operates globally, providing advanced diagnostic tests that help detect cancer at its earliest stages and guide treatment decisions. Exact Sciences serves healthcare providers, patients, and research institutions, operating in the medical diagnostics market. The company's business model revolves around the development, manufacturing, and sale of cancer screening and diagnostic tests, generating revenue primarily through test sales and partnerships with healthcare organizations. Exact Sciences aims to reduce the burden of cancer through innovative solutions and comprehensive support for patients and healthcare professionals.
Keywords: cancer diagnostics, early detection, biotechnology, healthcare, medical diagnostics, cancer screening, treatment guidance, global operations, healthcare providers, innovative solutions.